Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 11, 2010

Sigma-Aldrich Licenses RAFT Polymerization Technology from CSIRO

  • Sigma-Aldrich entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell reversible addition-fragmentation chain transfer (RAFT) agents, organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers. Under the terms of the agreement, Sigma-Aldrich has the rights to manufacture and sell the RAFT agents worldwide for all R&D applications.

    Polymers designed using RAFT technology can be used to prepare materials with unique properties controlled by their nanometer-scale molecular architecture in industries such as biomedical, specialty chemical, and personal care, Sigma-Aldrich explains. The RAFT method is applicable to a wide range of monomers and experimental conditions. Sigma-Aldrich currently offers seven RAFT agents that can be supplied in quantities from standard 1 g and 5 g packs to several hundred grams and expects to make additional RAFT agents available later in 2010.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »